ARCT News & Analysis

Arcturus Therapeutics (ARCT) Gains 5.8% on Thermo Fisher Deal

Arcturus Therapeutics (ARCT) experienced a 5.8% increase following an agreement with Thermo Fisher. This deal signifies a strategic collaboration that could enhance Arcturus' operational capabilities and market positioning. The market reacted positively, indicating investor confidence in the partnership's potential benefits. Overall, this development may influence Arcturus' future stock performance as it leverages the resources provided through this collaboration.